***Faster, User Friendly Cardio AI Imaging Product for Commercial Roll Out***

Toronto, Ont. — TheNewswire --- March 04, 2024 — Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) released a significant upgrade to the design and function of its whole-heart analysis system (VMS+3.2), which accelerates imaging, analysis and ease of use at the point of care.

The new design allows immediate calibration by technicians with existing ultrasound equipment  to more quickly generate 2D ultrasound images, which the VMS+3.2 turns into a high-definition 3D heart model. The upgraded system also includes an improved 3D visualization tool, which speeds up and facilitates the analysis of 3D ultrasound exams.

VMS+3.2 release improves the ease-of-use of 2D and 3D echocardiogram procedures for sonographers, cardiologists and caregivers, assuring seamless integration of Ventripoint technology into patient-care workflow and standard of care. In a busy echocardiography unit, reducing the time for a procedure without compromising the quality of the results is a constant challenge and the VMS+3.2 will be appreciated for these innovations.

“We are constantly improving the design of our system, to generate efficiencies and better outcomes,” said Ventripoint’s Interim CEO, Hugh MacNaught. “This is a best-in-class diagnostic tool that allows enhanced echocardiograms of infants and adults to be available faster and at less cost than a cardiac MRI, with equivalent structural and functional results.”

The new design removes the magnet from the probe-tracking system and so it is now immune to environments where magnetic fields are present and is no longer a concern for implanted patient medical devices, such as pacemakers and other cardiac devices, where magnets can be disruptive. The Company intends to submit to regulatory agencies for the removal of this limitation on the VMS+ system.  

Ventripoint’s technology is now being used in leading hospitals in Europe, the UK, Canada, China and the United States as an alternative to traditional MRI heart scans. These users will be offered the VMS+3.2 upgrade for a fee and future sales will be of the VMS+3.2 version.  The Company is now focused on expanding the user base in hospitals and clinics worldwide.

The Company has a world-class board of clinical advisors who continue to provide ideas for design improvements, which are ongoing.  The company expects to announce additional enhancements in 2024, which will require regulatory approvals and enable VMS+ to be used with a wider range of patients.  It is important to note that these future upgrades are software improvements, which can be seamlessly integrated into existing and new VMS+ units.

For further information, please contact:

Jonathan Robinson CFA

JRobinson@oakhillfinancial.ca

(416) 669-1001

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe, and Canada.

Forward Looking Statements

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends'' and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct.

Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to several factors and risks. Factors which could materially affect such forward-looking information are described in the risk factors in the Company's most recent annual management's discussion and analysis that is available on the Company's profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether because of new information, future events or otherwise, unless so required by applicable securities laws.